Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
ESR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ESR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ESR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABARAP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABARAP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GABARAP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ESRRG Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ESRRG Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ESRRG sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
C1QBP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
C1QBP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of C1QBP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CHRNE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHRNE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CHRNE sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ARHGAP45 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ARHGAP45 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ARHGAP45 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CHRND Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHRND Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CHRND sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CHRNA9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHRNA9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CHRNA9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TRPC5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TRPC5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TRPC5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TRPV3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TRPV3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TRPV3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TRPC6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TRPC6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TRPC6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TYK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TYK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TYK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →